What is the response rate for abexinostat in relapsed Follicular Lymphoma?
Abexinostat is an oral histone deacetylase inhibitor being studied for relapsed or refractory follicular lymphoma. In a recent phase 2 trial, the objective response rate (ORR) was 69.5%, meaning about 7 out of 10 patients had their tumors shrink or disappear. This is a promising result for patients who have already tried other treatments.
What the research says
A phase 2 study (NCT03934567) enrolled 90 patients with relapsed or refractory follicular lymphoma who had received at least two prior treatments 37. Patients took abexinostat 80 mg twice daily for 7 days on and 7 days off in 28-day cycles 37. The ORR was 69.5% (57 of 82 evaluable patients), with a complete response rate of 14.6% 37. The disease control rate (including stable disease) was 91.5% 37. Tumor size decreased in 89% of patients 37. The median duration of response was about 14 months, and median progression-free survival was about 13.8 months 37. An earlier phase 2 study from 2017 reported a lower ORR of 28% in a mixed group of non-Hodgkin lymphoma patients, but that study used a different dosing schedule (14 days on, 7 days off) 8. A phase 1 study in Chinese patients also found abexinostat to be safe and active, with 80 mg BID as the recommended dose 6.
What to ask your doctor
- Is abexinostat available for my type of relapsed follicular lymphoma, and is it approved by the FDA or other regulators?
- What are the common side effects of abexinostat, such as low platelets or fatigue, and how are they managed?
- How does abexinostat compare to other options I have, like lenalidomide or bispecific antibodies?
- Would I be eligible for any clinical trials testing abexinostat?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.